Horizon Pharma Public Limited Company (HZNP)
(Delayed Data from NSDQ)
$26.54 USD
+0.55 (2.12%)
Updated May 3, 2019 04:00 PM ET
After-Market: $26.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.54 USD
+0.55 (2.12%)
Updated May 3, 2019 04:00 PM ET
After-Market: $26.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Eleven Biotherapeutics (EBIO) in Focus: Stock Moves 8.7% Higher
by Zacks Equity Research
Shares of Eleven Biotherapeutics (EBIO) rose nearly 9% yesterday.
Zacks.com highlights: Western Digital, ArcelorMittal, Arrow Electronics and Horizon Pharma Public
by Zacks Equity Research
Zacks.com highlights: Western Digital, ArcelorMittal, Arrow Electronics and Horizon Pharma Public
Enhance Your Portfolio With These 5 Low Price-to-Book Stocks
by Zacks Equity Research
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.
Pick These 4 Low P/CF Stocks & Sail Through a Volatile Market
by Zacks Equity Research
Investment in stocks made on diligent value analysis is usually considered one of the best practices.
4 Drug/Biotech Stocks to Buy Ahead of World Health Day
by Indrajit Bandyopadhyay
Given the increase in population and incidence of diseases along with growing awareness and healthcare coverage initiatives, the drug sector is expected to grow.
Conatus' Emricasan Fails in Phase II Study, Shares Sink
by Zacks Equity Research
Conatus Pharmaceuticals' (CNAT) emricasan fails to meet the primary endpoint in a phase IIb study on liver transplant patients with fibrosis or cirrhosis.
Pick These 5 Winning Stocks Based on a Favorable P/B Ratio
by Zacks Equity Research
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.
Amgen's Blincyto Gets FDA Nod for Minimum Residual Disease
by Zacks Equity Research
Amgen's (AMGN) leukemia drug, Blincyto is the first approved drug for the treatment of minimal residual disease in the United States.
Horizon Pharma (HZNP) Down 3.9% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Horizon Pharma (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is a Recession in the Cards? 4 Safe Bets for Your Portfolio
by Indrajit Bandyopadhyay
After nearly a decade of the global financial crisis of 2007-2008, some analysts believe that the threat of another recession lurks. However, the time and its impact is yet to be ascertained.
Protagonist Therapeutics Stalls Ulcerative Colitis Study
by Zacks Equity Research
Protagonist Therapeutics' (PTGX) shares plunge more than 50%, following discontinuation of a mid-stage study on its key ulcerative colitis candidate, PTG-100.
Pfizer's Chantix Fails in Phase IV Study in Young Smokers
by Zacks Equity Research
Pfizer's (PFE) Chantix fails to meet primary endpoint in a phase IV study, a regulatory post-marketing commitment.
Clovis Gets Positive CHMP Opinion for Ovarian Cancer Drug
by Zacks Equity Research
Clovis' (CLVS) ovarian cancer drug, Rubraca, gets positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency.
Regeneron Collaborates With Alnylam to Develop NASH Treatment
by Zacks Equity Research
Regeneron Pharmaceuticals (REGN) enters a collaboration with Alnylam to discover and develop RNAi-based therapies for treatment of NASH.
Seattle Genetics' Adcetris Gets FDA Nod for Label Expansion
by Zacks Equity Research
Seattle Genetics' (SGEN) cancer drug, Adcetris, gets FDA approval to include fifth indication, frontline treatment of advanced classical Hodgkin lymphoma, in its label.
Ignore Trump's Pricing Rhetoric With These 5 Biotech Picks
by Swarup Gupta
Industry watchers have grown skeptical about Trump's intermittent pronouncements on this issue.
Heron's Pain Candidate Meets Endpoint in Pivotal Studies
by Zacks Equity Research
Heron Therapeutics' (HRTX) pipeline candidate, HTX-011, meets primary endpoint in two pivotal phase III studies in bunionectomy and hernia repair.
Arena's (ARNA) Etrasimod Meets Phase II Colitis Study Goal
by Zacks Equity Research
Arena's (ARNA) ulcerative colitis candidate, etrasimod leads to clinical remission in 33% of the patients.
5 Valuable Price-to-Book Stocks to Boost Your Portfolio
by Zacks Equity Research
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.
Geron (GERN) Q4 Loss Flat Y/Y, Revenues Surge, Shares Up
by Zacks Equity Research
Geron (GERN) misses earnings and sales estimates in Q4. However, revenues almost double year over year. Imetelstat remains in focus.
Is Horizon Pharma Public (HZNP) a Great Stock for Value Investors Right Now?
by Zacks Equity Research
Horizon Pharma (HZNP) is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.
5 Discounted PEG Stocks for Value Investors
by Zacks Equity Research
PEG-based investing can turn out to be more rewarding if some other relevant parameters are taken into consideration.
Sarepta to Seek Rapid Approval for Second DMD Drug, Stock Up
by Zacks Equity Research
Sarepta (SRPT) will file a rolling NDA for its second DMD drug, golodirsen. The submission is expected to be completed in late 2018.
Zacks.com highlights: TheStreet, Barclays, Horizon Pharma, Regions Financial and TechTarget
by Zacks Equity Research
Zacks.com highlights: TheStreet, Barclays, Horizon Pharma, Regions Financial and TechTarget
5 Cheap Breakout Stocks for Explosive Returns
by Swarup Gupta
The technique seeks to identify stocks whose prices are fluctuating within a specific band.